Around 6,600 people in England with a serious heart condition will be able to access a new treatment following simultaneous MHRA authorisation and NICE approval today. Aficamten, also known as Myqorzo, is a once-daily pill for people with obstructive hypertrophic cardiomyopathy (HCM) - a condition where the heart muscle becomes thickened and stiff, making it harder for the heart to pump blood around the body. It can cause exhaustion, dizziness, breathlessness, chest pain and a racing or irregular heartbeat. Around 1 in 500 people in the UK has HCM, and in roughly half of cases it is inherited. Clinical trials show aficamten helps people exercise more easily and reduces their symptoms. It is likely to be as effective as mavacamten, the
UK NICE · July 30, 2026
NICE approval: aficamten (Myqorzo) for obstructive hypertrophic cardiomyopathy
Original title: Thousands of patients to benefit from new daily pill for serious heart condition
NICE recommends funding aficamten for around 6,600 people in England with obstructive hypertrophic cardiomyopathy following MHRA authorisation.
Published by UK NICE. HealthSignal links to the original document; the summary above is extracted from the source text.